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Abstract
Background: There is a vast amount of information published regarding the impact of 2009 pandemic Influenza A
(pH1N1) virus infection. However, a comparison of risk factors and outcome during the 2010-2011 post-pandemic
period has not been described.
Methods: A prospective, observational, multi-center study was carried out to evaluate the clinical characteristics
and demographics of patients with positive RT-PCR for H1N1 admitted to 148 Spanish intensive care units (ICUs).
Data were obtained from the 2009 pandemic and compared to the 2010-2011 post-pandemic period.
Results: Nine hundred and ninety-seven patients with confirmed An/H1N1 infection were included. Six hundred
and forty-eight patients affected by 2009 (pH1N1) virus infection and 349 patients affected by the post-pandemic
Influenza (H1N1)v infection period were analyzed. Patients during the post-pandemic period were older, had more
chronic comorbid conditions and presented with higher severity scores (Acute Physiology And Chronic Health
Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA)) on ICU admission. Patients from the
post-pandemic Influenza (H1N1)v infection period received empiric antiviral treatment less frequently and with
delayed administration. Mortality was significantly higher in the post-pandemic period. Multivariate analysis
confirmed that haematological disease, invasive mechanical ventilation and continuous renal replacement therapy
were factors independently associated with worse outcome in the two periods. HIV was the only new variable
independently associated with higher ICU mortality during the post-pandemic Influenza (H1N1)v infection period.
Conclusion: Patients from the post-pandemic Influenza (H1N1)v infection period had an unexpectedly higher
mortality rate and showed a trend towards affecting a more vulnerable population, in keeping with more typical
seasonal viral infection.
Introduction
There is a vast amount of information published regard-
ing the impact of the 2009 pandemic Influenza A
(H1N1)v infection [1,2]. The pandemic represented a
challenge for physicians worldwide, manifesting with the
acute onset of respiratory failure in a patient population
often young, with few comorbid conditions. Several
recommendations have been considered, taking into
account the literature published during this time. The
early use of oseltamivir showed a survival benefit [3,4],
while the use of systemic corticosteroids did not [5,6].
Identification of risk factors, such as the presence of
community acquired respiratory co-infection (CARC)
[7], obesity [8] and the development of acute kidney
injury, have helped physicians gain a better understand-
ing of the illness [9].
Health authorities warned that clinical suspicion
should be maintained following the initial pandemic,
with a post-pandemic period predicted for the 2010-
2011 winter as a result of the former A/H1N1 2009
pandemic virus, currently called “new A/H1N1 virus”
(An/H1N1) [10].
The aim of the present study was to compare risk fac-
tors, clinical features and outcomes in pandemic
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immediate post-pandemic influenza period.
Material and methods
This prospective, observational cohort study of intensive
care unit (ICU) patients was conducted across 148 ICUs
in Spain. Data were obtained from a voluntary registry
created by the Spanish Society of Intensive Care Medi-
cine (SEMICYUC), the Spanish Network for Research
on Infectious Disease (REIPI) and the Spanish Biomedi-
cal Research Center Network on Respiratory Diseases
(CIBERES). The study was approved by the Joan XXIII
University Hospital Ethics Committee (IRB NEUMA-
GRIP/11809). Patient identification remained anon-
ymous. The requirement for informed consent was
waived due to the observational nature of the study and
the fact that this activity is an emergency public health
response as reported elsewhere [11].
Data were reported by the attending physician after
reviewing medical charts and radiological and laboratory
records. Two periods were analyzed based on data on
all patients within the cohort consecutively diagnosed
with An/H1N1 influenza: the 2009 pandemic (H1N1)v
infection period between epidemiological weeks 23 and
52 of 2009, and the post-pandemic Influenza (H1N1)v
infection period between epidemiological weeks 50 and
52 of 2010 and weeks 1 to 9 of 2011. Children under 15
years old were not enrolled in the registry. The An/
H1N1 infection was confirmed by means of real-time
reverse-transcription-polymerase chain reaction (RT-
PCR) on either nasopharyngeal swab samples or tracheal
secretions ordered by the attending physicians at inten-
sive care unit (ICU) admission. An/H1N1 testing was
performed in each institution or centralized in a refer-
ence laboratory when local resources were not available.
RT-PCR methods and further details are described else-
where [11]. A confirmed case was defined as an acute
respiratory illness with laboratory-confirmed An/H1N1.
Only confirmed cases were included in the current
report.
The ICU admission criteria and treatment decisions
for all patients, including determination of the need for
intubation and type of antibiotic or antiviral therapy
administered, were made at the discretion of the attend-
ing physician and not standardized. Septic shock and
Multiple Organ Dysfunction Score (MODS) were
defined following the criteria of the American College of
Chest Physicians and the Society of Critical Care Medi-
cine [12].
Systemic corticosteroid use was implemented when
patients developed shock (hydrocortisone), or coadju-
vant treatment was used for pneumonia (methylpredni-
solone). Orally administered oseltamivir (150 mg/24 h
or 300 mg/24 h) or intravenous zanamivir (600 mg/12
h) was chosen by the attending physician.
Primary viral pneumonia was defined where patients
presented with acute respiratory distress, unequivocal
alveolar opacities involving two or more lobes, and
negative respiratory and blood bacterial cultures during
the acute phase of influenza virus infection. Commu-
nity-Acquired Respiratory Co-infection (CARC) was
defined as any infection diagnosed within the first two
days of hospitalization [7]. Infections occurring later
were considered nosocomial. hospital-acquired pneumo-
nia (HAP) was defined based on current American
Thoracic Society and Infectious Disease Society of
America guidelines [13]. Patients who presented with
healthcare-associated pneumonia (HCAP) were excluded
from the present study [13]. Hematological disease was
defined in those patients who presented with acute lym-
phoblastic leukemia, acute myeloblastic leukemia,
chronic lymphocytic leukemia, chronic myelogenous
leukemia, Hodgkin’s lymphoma, non-Hodgkin’sl y m -
phoma, myeloma, graft versus host disease or post-bone
marrow transplantation. Obese patients were defined as
those with a body mass index (BMI) greater than 30 kg/
m
2 [8]. Features such as smoking history and immuno-
suppressive factors were not recorded. Patients who had
previously received Influenza A (H1N1) 2009 monova-
lent or seasonal influenza 2010-2011 vaccination were
considered to be “vaccinated”. Acute kidney injury (AKI)
and its stages were diagnosed according to the glomeru-
lar filtration rate (GFR) criteria of the current Acute
Kidney Injury Network definitions [14]. Diagnostic cri-
teria for acute kidney injury (AKI): An abrupt (within 48
hours) reduction in kidney function currently defined as
an absolute increase in serum creatinine of more than
or equal to 0.3 mg/dl, a percentage increase in serum
creatinine of more than or equal to 50% (1.5-fold from
baseline), or a reduction in urine output (documented
oliguria of less than 0.5 ml/kg per hour for more than
six hours) [14]. Continuous Renal Replacement Therapy
(CRRT) in the course of AKI was initiated when indi-
cated for pulmonary edema, oliguria (defined as urine
output <0.5 mL/kg body weight per hour for >6 h),
metabolic acidosis or hyperkalaemia not responding to
conventional treatment, or uraemia (defined as urea
nitrogen of >100 mg/dL). CRRT was available 24 hours
a day, and no patient requiring CRRT was denied treat-
ment due to likely futility.
Statistical analysis
Discrete variables are expressed as counts (percentage)
and continuous variables as means ± standard deviation
(SD) or medians with the 25th to 75th interquartile
range (IQR). For the demographic and clinical
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groups were assessed using the chi-squared test or Fish-
er’s exact test for categorical variables and the Student’s
t-test or Mann-Whitney U test for continuous variables
when appropriate. Multivariable stepwise logistic regres-
sion analysis was used to assess the impact of explana-
tory variables in outcome (ICU mortality) for both the
pandemic and post-pandemic periods. In order to avoid
spurious associations, variables entered in the logistic
regression models were those with a relationship in uni-
variate analysis (P ≤0.1) or a potential plausible relation-
ship with the outcome. To assess the possibility of a
different impact of the explanatory variables in outcome
for each period, interactions between explanatory vari-
ables and periods were used in the models. Results are
presented as odds ratio (OR), 95% confidence intervals
(CI) and P-values. Data analyses were performed using
SPSS 16.0 for Windows (SPSS, Chicago, IL, USA).
Results
Nine hundred and ninety-seven patients with completed
outcomes admitted to ICU with confirmed Influenza
(H1N1)v infection were analyzed in this study. Of these,
648 patients were affected during the 2009 pandemic
Influenza (H1N1)v infection period and 349 patients dur-
ing the post-pandemic Influenza (H1N1)v infection period.
Patients from the post-pandemic Influenza (H1N1)v
infection period were older, more frequently male and
presented with more comorbidities than those affected
by the 2009 pandemic Influenza (H1N1)v infection.
Comorbidities included chronic obstructive pulmonary
disease (COPD), chronic renal disease and hematological
disease. Pandemic and post-pandemic age-specific influ-
enza ICU admission baseline characteristics are dis-
played in Figure 1. Vaccination was only available in
Spain during the post-pandemic period. A total of 19
(5.4%) received vaccination. Vaccination was more fre-
quent in patients who presented with comorbidities
than those who did not (18 (7.0%) vs. 1 (1.1%), P =
0.02). There was no difference in time to diagnosis
between vaccinated and non-vaccinated patient groups
(6 IQR (4 to 8) vs. 8 IQR (5 to 11), P=0.1. No particu-
lar comorbid condition was predominant in those vacci-
nated. Additional demographic data and clinical
characteristics regarding delay in diagnosis and vaccina-
tion status are displayed in Table 1.
A c u t eP h y s i o l o g yA n dC h r o n i cH e a l t hE v a l u a t i o n
(APACHE II) and Sequential Organ Failure Assessment
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Figure 1 Pandemic and post-pandemic age-specific influenza ICU admission.
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Page 3 of 11(SOFA) scores were higher in post-pandemic Influenza
(H1N1)v infection patients. In addition, this cohort of
patients was admitted later to the hospital from time of
symptom onset (4.2 +/- 2.6 vs. 4.8 +/- 3.4, P =0 . 0 0 4 )
and had a longer delay from time of hospitalization to
diagnosis (2.3 +/- 2.1 vs.6.5 +/- 3.8, P <0.001). Primary
viral pneumonia was documented in 688 (69.0%)
patients with no significant difference between the two
periods. In 176 (17.7%) cases another pathogen was iso-
lated at ICU admission and these patients were consid-
ered to have CARC.
Empiric antibiotic therapy was administered in all
patients in accordance with local protocols. Post-pan-
demic Influenza (H1N1)v infection patients received
empiric antiviral treatment less frequently (99.1% vs.
97.4%, P = 0.04), lower doses of oseltamivir (150 mg/
day) (73.5% vs. 51.5%, P <0.001), delayed antiviral
administration (5.6 +/- 3.5 vs. 4.7 +/- 2.9 days, P
<0.001), and had higher use of zanamivir (7.2% vs. 0.6%,
P <0.001) than those from the 2009 pandemic Influenza
(H1N1)v infection period.
Comparison of complications during ICU stay was dif-
ferent between the two periods. Septic shock was pre-
sent more frequently in the post-pandemic Influenza
(H1N1)v infection period (54.4% vs. 45.4%, P = 0.007).
Patients affected during the post-pandemic Influenza
(H1N1)v infection period received mechanical ventila-
tion (invasive or non-invasive) more frequently (80.8%
vs. 71.8%, P = 0.002); however, there was no significant
difference in implementation of invasive mechanical
ventilation. Extracorporeal membrane oxygenation
(ECMO) (n = 9) was more frequently implemented
during the post-pandemic Influenza (H1N1)v infection
period (1.7% vs. 0.5%, P = 0.07). AKI was more fre-
quently identified during the post-pandemic Influenza
(H1N1)v infection period (27.2% vs. 20.1%, P =0 . 0 1 )
with the use of CRRT significantly different between the
two periods. Further details are displayed in Table 2.
In total, 246 (24.7%) patients died. No statistical differ-
ence in survival was observed between patient groups
with respect to vaccination status (6 (5.7%) vs. 13
(5.3%), P=0.8). The median age for non-survivors was
significantly higher in the post-pandemic period (42
years (54 to 61.5) vs. 36 years (IQR 47 to 61), P
<0.001)). Mortality was significantly higher in the post-
pandemic Influenza (H1N1)v infection period compared
to the 2009 pandemic (H1N1)v infection period (105
(30.1%) vs. 141(21.8%) OR 1.5 (95% CI 1.1 to 2.1)). The
baseline characteristics ofp a t i e n t si nb o t hg r o u p sw h o
did not survive are compared in Table 3. Briefly, during
the 2009 pandemic (H1N1)v infection period, APACHE
II score, SOFA score, age, congestive heart failure,
chronic renal disease, hematological disease, CARC, sep-
tic shock, MODS, invasive mechanical ventilation (MV)
and CRRT were variables associated with ICU mortality
(univariate analysis). APACHE II score, SOFA score,
hematological disease, HIV, CARC, septic shock,
MODS, invasive MV and CRRT were associated vari-
ables during the post-pandemic Influenza (H1N1)v
infection period. Multivariate analysis (Table 4) con-
firmed that among patients in both groups the presence
of hematological disease, the use of invasive MV, and
CRRT were factors independently associated with a
worse outcome. HIV was the only new variable
Table 1 Comparison of baseline characteristics between 2009 pandemic and post-pandemic Influenza (H1N1)v
infection period
Variables Pandemic period
N = 648
Post-pandemic period
N = 349
P-value
Age. years
Mean (SD) 44.7 +/- 14.6 49.9 +/- 14.2 <0.001
Median (IQR) 34 (44 to 54) 40 (51 to 59) <0.001
Male (sex) n (%) 374 (57.7) 237 (67.9) 0.01
COPD n (%) 108 (16.7) 78 (22.3) 0.02
Asthma n (%) 81 (12.5) 28 (8.0) 0.03
Chronic heart failure n (%) 47 (7.3) 36 (10.3) 0.09
Chronic renal disease n (%) 33 (5.1) 30 (8.6) 0.03
Diabetes mellitus n (%) 82 (12.7) 55 (15.8) 0.1
Pregnancy n (%) 31 (4.8) 13 (3.7) 0.4
Obesity n (%) 138 (21.3) 64 (18.3) 0.2
Autoimmune disorders n (%) 18 (3.4) 2(1.8) 0.5
Hematological disease n (%) 40(6.2) 37 (10.6) 0.01
Neuromuscular disease n (%) 24 (3.7) 4 (1.1) 0.02
HIV infection n (%) 13 (2.0) 13 (3.7) 0.1
Abbreviations: CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; DM, diabetes mellitus; HIV, human
immunodeficiency virus; NM, neuromuscular
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Page 4 of 11independently associated with higher ICU mortality dur-
ing the post-pandemic influenza (H1N1)v infection per-
iod. In addition, the only interaction statistically
significant was between the presence of HIV and the
post-pandemic Influenza (H1N1)v infection period.
Discussion
Data from this study evidenced that the post-pandemic
Influenza (H1N1)v infection period targeted patients
with a worse basal condition than those of the 2009
pandemic (H1N1)v infection period. Patients from the
post-pandemic period were older, had more comorbid-
ities, a more advanced clinical presentation on admis-
sion, higher severity scores, increased incidence of
CARC and septic shock, and an increased requirement
for mechanical ventilation than those from the pan-
demic period. In addition, patients from the post-pan-
demic period had a higher mortality rate.
Experiences during the post-pandemic Influenza
(H1N1)v infection period have demonstrated that the
2009 pandemic (H1N1) virus is still circulating and,
importantly, still causing severe disease in younger
people [10,15-17]. During the immediate post-pandemic
period multiple subtypes of influenza virus were ana-
lyzed in order to evaluate the isolation of other types of
influenza viruses. The Ministry of Health reported that
98% of isolates were Influenza A (0.02% AH1; 0.08%
AH1N1; 0.09 AH3; 0.33% AH3N2 and 99.5%
2009AH1N1), 1.4% Influenza B and 0.1% Influenza C
[16].
Current World Health Organization (WHO) guidance
strongly recommends the use of oseltamivir for severe
or progressive infection with 2009 pandemic (H1N1)v
infection, with zanamivir as an alternative if the infect-
ing virus is oseltamivir-resistant [17]. Although the
majority of 2009 pandemic (H1N1) viruses are suscepti-
ble to oseltamivir and very little resistance to oseltamivir
has been found to date [18], the use of zanamivir has
been 12 times more frequent during the post-pandemic
Influenza (H1N1)v infection period. Previous studies
[3,4] have shown that early oseltamivir administration
resulted in increased survival among critically ill, venti-
lated patients and reduced complications in patients
hospitalized during the 2009 pandemic (H1N1)v
Table 2 Comparison of clinical presentation and therapy provided between 2009 pandemic and post-pandemic
Influenza (H1N1)v infection period.
Variables Pandemic period
N = 648
Post-pandemic period
N = 349
P-value
APACHE II score.
Mean (SD)
13.9 +/- 7.2 16.3 +/- 7.7 <0.001
SOFA score.
Mean (SD)
5.6 +/- 3.6 6.2 +/- 4.1 0.04
Clinical presentation
Primary viral pneumonia 451 (69.6) 237 (67.9) 0.5
COPD exacerbation 36 (5.6) 24 (6.9) 0.4
Community acquired respiratory co-infection 107 (16.5) 69 (19.8) 0.2
Secondary respiratory infections 57 (9.3) 16 (4.7) 0.006
Days from symptoms onset to hospital admission, Mean (SD) 4.2 +/- 2.6 4.8 +/- 3.4 0.004
Days from hospitalization to diagnosis, Mean (SD) 2.3 +/- 2.1 6.5 +/- 3.8 <0.001
Clinical failure
Septic shock 294 (45.4) 190 (54.4) 0.006
MODS 405 (62.5) 199 (57) 0.09
Mechanical ventilation 465 (71.8) 282 (80.8) <0.001
Invasive mechanical ventilation 398 (61.4) 233 (66.8) 0.09
Non-invasive mechanical ventilation 163 (25.2) 115 (33) <0.001
Prone positioning 95 (14.7) 67 (19.2) 0.06
Septic shock 294 (45.4) 190 (54.4) 0.007
Acute kidney Injury 130 (20.1) 95 (27.2) <0.001
Continuous renal replacement therapy 53 (8.2) 45 (12.9) <0.001
Therapy administered
Empirical oseltamivir 631 (99.1) 339 (97.4) 0.04
Days from symptoms onset to oseltamivir administration 4.7 (2.9) 5.6 (3.5) <0.001
Zanamivir 4 (0.6) 25 (7.2) <0.001
ICU mortality 141 (21.8) 105 (30.1) 0.004
Abbreviations: ICU, intensive care unit; MODS, multiple organ dysfunction syndrome
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Page 5 of 11Table 3 Risk factors for ICU mortality for 2009 pandemic and post-pandemic Influenza (H1N1)v infection patients.
Variable Pandemic period
N = 648
Post-pandemic period
N = 349
Risk factor Alive
(n = 507)
Death
(n = 141)
P-value Alive
(n = 244)
Death
(n = 105)
P-value
SOFA 4.9 (3.0) 8.4 (4.3) <0.001 5.1 (3.5) 8.6 (4.1) <0.001
APACHE 12.53 (6.1) 19.69 (8.3) <0.001 14.11 (6.1) 21.2 (8.5) <0.001
Demographics
Age. Mean (SD) 43.72 (14.0) 48.4 (16.3) <0.001 49.0 (14.1) 52.0 (14.3) 0.07
Male sex 285 (56.2) 89 (63.1) 0.14 162 (66.4) 75 (71.4) 0.35
Comorbidities
≥1 underlying medical conditions 353 (69.6) 112 (79.4) 0.02 177 (72.5) 81 (77.1) 0.3
COPD 87 (17.2) 21(14.9) 0.52 52 (21.3) 26 (24.8) 0.47
Asthma 69 (13.6) 12 (8.5) 0.105 23 (9.4) 5 (4.8) 0.14
Chronic heart failure 31(6.1) 16(11.3) 0.03 23(9.4) 13(12.4) 0.41
Chronic renal disease 19 (3.7) 14 (9.9) 0.003 18 (7.4) 12 (11.4) 0.21
Diabetes mellitus 62 (12.2) 20 (14.2) 0.53 41(16.8) 14 (13.3) 0.41
Obesity 104 (20.5) 34 (24.1) 0.35 50 (20.5) 14 (13.3) 0.11
Autoimmune disease 13 (2.6) 8 (5.7) 0.06 7 (2.9) 7 (6.7) 0.09
Hematologic disease 19 (3.7) 21 (14.9) <0.001 14 (5.7) 23 (21.9) <0.001
Neuromuscular disease 18 (3.6) 6 (4.3) 0.69 2 (0.8) 2 (1.9) 0.38
HIV infection 9 (1.8) 4 (2.8) 0.42 2 (0.8) 11 (10.5) <0.001
Pregnancy 24 (4.7) 7 (5) 0.9 11 (4.5) 2 (1.9) 0.2
Vaccination 13 (5.3) 6 (5.7) 0.8
Clinical presentation
Viral pneumonia 355 (70) 96 (68.1) 0.6 164 (67.2) 73 (69.5) 0.6
COPD exacerbation 31 (6.1) 5 (3.5) 0.2 21 (8.6) 3 (2.9) 0.05
Community acquired respiratory
co-infection
74 (14.6) 33 (23.4) 0.01 38 (15.6) 31 (29.5) 0.003
Complications
Septic shock 190 (37.5) 104 (73.8) <0.001 106 (43.4) 84 (80) <0.001
MODS 282 (55.6) 123 (87.2) <0.001 111 (45.5) 88 (83.8) <0.001
Acute kidney injury 69 13.6) 61 (43.3) <0.001 43 (17.6) 52 (49.5) <0.001
Therapy administered
Empirical oseltamivir 497(99.6) 134 (97.1) 0.002 238 (97.9) 101 (96.2) 0.1
Continuous renal replacement therapy 15 (3.0) 38 (27.0) <0.001 12 (4.9) 33 (31.4) <0.001
Mechanical ventilation 327 (64.5) 138 (97.9) <0.001 181 (74.2) 101 (96.2) <0.001
Invasive mechanical ventilation 263(51.9) 135(95.7) <0.001 135(55.3) 98(93.3) <0.001
Non-invasive mechanical ventilation 125(24.7) 38(27.3) 0.5 86(35.7) 29(27.6) 0.1
Abbreviations: CARC, community acquired respiratory co-infection; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; ICU,
intensive care unit; MODS, multiple organ dysfunction syndrome
Table 4 Multivariate analysis for risk factors associated with ICU mortality during the 2009 pandemic and post-
pandemic Influenza (H1N1)v infection period.
Variable OR 95% CI P-value
APACHE II score 1.076 1.040 to 1.114 <0.001
Hematologic disease 3.506 1.747 to 7.038 <0.001
Continuous renal replacement therapy 5.812 3.101 to 10.893 <0.001
Invasive mechanical ventilation 6.890 3.538 to 13.418 <0.001
HIV infection in pandemic Influenza (H1N1)v infection period * 1.362 0.279 to 6.648 0.702
HIV infection in post-pandemic Influenza (H1N1)v infection period * 19.835 2.236 to 175.954 0.007
The interaction HIV infection with period was statistically significant (P-value = 0.05).
Abbreviations: HIV, human immunodeficiency virus; ICU, intensive care unit
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Page 6 of 11infection period. In addition, oseltamivir suppresses viral
load more effectively when given early [19,20]. It is
important to recognize that the early control of viral
load in patients may be explained by the actions of
innate immunity followed by early anamnestic adaptive
immune response [21]. The lack of an appropriate and
early immune response because of innate humoral or
cellular immunodeficiencies, concomitant use of immu-
nosuppressors, or transient immunoparesis due to
severe concomitant co-infection may predispose some
patients to develop severe clinical progression [22]. The
incidence of HIV was 2% and 3.7% during the 2009 pan-
demic (H1N1)v infection period and post-pandemic
Influenza (H1N1)v infection period respectively, but,
interestingly, HIV was the only independent additional
factor associated with higher ICU mortality in the post
pandemic period. As previously reported, HIV patients,
well controlled on Highly Active Antiretroviral Therapy
(HAART), had a similar clinical outcome and prognosis
to that of non-HIV patients during the pandemic period
[23]]. However, in our study, HIV appeared to be a new
independent risk factor for worse outcome. The
immune response associated with severe viral infections
remains unclear in HIV patients and needs to be further
investigated, as the virus was no longer acting in a naive
host.
While in 2009 the new virus found large numbers of
people with no previous immunity against it, in 2010-
2011 the situation dramatically changed. Large numbers
of people had already received the vaccine, or alterna-
tively had acquired natural immunity following infection
by the time that the 2010-2011 season started. This cre-
ated a more difficult environment for the virus to thrive,
with a decreased percentage of susceptible individuals. It
is plausible that with these changes in the population
the virus would preferentially target hosts with chronic
comorbidities, such as COPD, diabetes or HIV patients
with altered cellular immunity. These conditions could
potentially impair the efficiency of the immune response
in clearing the infection. Proportional changes of the
susceptible population could explain the observed differ-
ences in the profile of critically ill patients infected and
the increased severity at admission to ICU. This trend is
closer to the “normal” behaviour of seasonal influenza.
One important feature in both phases was the pre-
sence of acute respiratory failure as reflected by the
need for invasive mechanical ventilation as an indepen-
dent predictor of death. This finding is compatible with
viral pneumonia being the principal cause of death in
these patients and reinforces the role of the virus in
causing critical illness. Despite the fact that non-invasive
mechanical ventilation was not recommended for the
management of patients affected by H1N1, its use was
observed in 33% of cases in the post-pandemic Influenza
(H1N1)v infection period. This finding may explain the
delay in onset of invasive mechanical ventilation and a
subsequently worse outcome during this period. It is
important to recognise that the presence of neither
CARC nor septic shock were independently associated
with ICU mortality.
T h ep r e s e n c eo fC A R Ch a sb e e nat o p i cc o m m o n l y
discussed during previous pandemics [7]. A substantial
base of laboratory evidence for synergism between Influ-
enza A and bacterial microorganisms has been sug-
gested [24]. During the 1918-1919 Influenza A
pandemic, most deaths were attributed to concurrent
bacterial infection [25]. Histopathological samples of
lung tissue sections from fatal 1918 influenza case mate-
rials frequently revealed histopathologic findings consis-
tent with acute bacterial pneumonia [26]. Nevertheless,
this data result is surprising since CARC did not repre-
sent an independent risk factor for ICU mortality during
either the 2009 pandemic (H1N1)v infection period or
during the post-pandemic Influenza (H1N1)v infection
period. While many studies [27] have demonstrated
temporal relationships between influenza activity and
CARC, and also an increasing number of patients
affected by CARC during the post-pandemic period, the
present study did not show significant differences
between the two periods.
During the first case reports of the 2009 pandemic
(H1N1)v infection period, impairment of renal function
was commonly observed and patients who died had
documented multiple organ failure with significantly
higher rates of renal failure [28]. AKI is a complex dis-
order that has been observed to occur in ICU patients
with severe presentation of illness during the 2009 pan-
demic (H1N1)v infection period [29], and it has been
associated with increased mortality rates. Interestingly,
the rate of AKI was significantly higher during the post-
pandemic Influenza (H1N1)v infection period (27.2% vs.
20.1%, P <0.001) and, as has been reported previously
[9], is associated with an increase in ICU mortality dur-
ing the post-pandemic period. The cause-and-effect rela-
tionship between viral infection and kidney injury is not
clear, nor is the reason for an increased incidence in the
post-pandemic period. Glomerular deposition of viral
antigen, cytokine dysregulation associated with severe
viral infection, and virus-related rhabdomyolysis might
partially explain the pathophysiology of AKI. However,
there are several factors that might contribute to an
increased incidence during the post-pandemic period.
First, patients admitted in the post-pandemic period
were older and presented with a higher severity of ill-
ness. Second, patients admitted in the post-pandemic
period had a longer delay between diagnosis and onset
for antiviral therapy. Finally, a higher incidence of septic
shock might contribute to an increase in AKI. The
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patients with H1N1 have not been clearly elucidated,
and further research is needed in order to allow early
identification of the subject at risk and provide targeted
medical care.
The present study has some limitations that should be
addressed. First, only adults admitted to Spanish ICUs
were included and, therefore, our results might not be
generalized to other countries or children. However, our
study included more than 70% of all patients admitted
to the ICU during the pandemic and post-pandemic
Influenza (H1N1)v infection periods. Management of
patients was not standardized and management prac-
tices were chosen in accordance with local protocols.
Nevertheless, it has the strength of a prospective, multi-
center design with a large number of patients. ECMO
was rarely implemented in Spain (n = 9, 0.9%) and,
therefore, no conclusions can be reached. Second,
patients presenting in the post-pandemic Influenza
(H1N1)v infection period had a delay in diagnosis, but
time to diagnosis might be a non-objective parameter
that depends on patient experience, the grade of physi-
cian and index of suspicion. Moreover, the unavailability
of daily RT-PCR in some institutions during the post-
pandemic period could prolong the time to diagnosis.
Finally, the CD4 count was not recorded in HIV
patients. Based on the epidemiological nature of the
s t u d yo n l yp a t i e n t sd i a g n o s e dw i t hH I Vw e r ei n c l u d e d
in the group. It is important to note that some patients
d e v e l o pal o wC D 4c o u n tw h e nc r i t i c a l l yi l l[ 3 0 ] .I n
addition, low CD4 cell counts, time since HIV diagnosis,
HAART treatment or AIDS stage of disease; conversely,
have not been identified as risk factors for ICU mortality
in the post-HAART era [31]. Therefore, CD4 count in
HIV patients should be further investigated. Finally, the
marked change in time to diagnosis also suggests that
there was laxity in testing during the present study.
Cases may have been missed in the post-pandemic per-
iod with selection bias contributing to observed
differences.
Conclusions
In summary, pandemics, like the viruses that cause
them, are unpredictable. So was the immediate post-
pandemic Influenza (H1N1)v infection period. The main
findings were that the mortality rate and severity scores
were higher in the post-pandemic period. A lower clini-
cal awareness and a more vulnerable population may
explain the worse outcome in the post-pandemic period.
The development of protocols, educational programs
and prevention recommendations need to be implemen-
ted to avoid further diagnosis and treatment delays. As
was previously warned [10], physicians should maintain
a high level of clinical suspicion for future waves in
order to prevent the unexpected increase in mortality
observed in this study.
Key messages
￿ The mortality rate and severity scores were higher
in the post-pandemic Influenza (H1N1)v infection
period.
￿ During the post-pandemic Influenza (H1N1)v
infection period, patients were older, with more
comorbidities and with delayed hospital admission.
￿ A more vulnerable population was affected in the
post-pandemic Influenza (H1N1)v infection period.
￿ HIV was the only new variable independently asso-
ciated with higher ICU mortality during the post-
pandemic Influenza (H1N1)v infection period.
Abbreviations
AKI: acute kidney injury; AKIN: Acute Kidney Injury Network: APACHE II: Acute
Physiology and Chronic Health Evaluation II; BMI: body mass index; CAP:
community-acquired pneumonia; CARC: Community Acquired Respiratory
Co-Infection; CDC: Centers for Disease Control and Prevention; CI:
confidence interval; CIBERES: Spanish Biomedical Research Center Network
on Respiratory Diseases; CK: creatinine kinase; COPD: chronic obstructive
pulmonary disease; CRRT: continuous renal replacement therapy; GFR:
glomerular filtration rate; HAART: Highly Active Antiretroviral Therapy; HIV:
human immunodeficiency virus; OR: odds ratio; HAP: hospital-acquired
pneumonia; HCAP: healthcare-associated pneumonia; ICU: intensive care
unit; IQR: interquartile range; MODS: Multiple Organ Dysfunction Score; MV:
mechanical ventilation; OR: odds ratio; REIPI: Spanish Network for Research
on Infectious Disease; RRT: renal replacement therapy; RT-PCR: real-time
polymerase chain reaction; SD: standard deviation; SEMICYUC: Spanish
Society of Intensive Care Medicine; SOFA: Sequential Organ Failure
Assessment; WHO: World Health Organization.
Acknowledgements
We are indebted to Craig Dunlop for English language editing.
H1N1 SEMICYUC/REIPI/CIBERES Working Group investigators
Andalucía:
Pedro Cobo (Hospital Punta de Europa, Algeciras); Javier Martins
(Hospital Santa Ana Motril, Granada); Cecilia Carbayo (Hospital
Torrecardenas, Almería); Emilio Robles-Musso, Antonio Cárdenas, Javier
Fierro (Hospital del Poniente, Almería); Dolores Ocaña Fernández
(Hospital Huercal - Overa, Almería); Rafael Sierra (Hospital Puerta del
Mar, Cádiz); Mª Jesús Huertos (Hospital Puerto Real, Cádiz); Juan Carlos
Pozo, R. Guerrero (Hospital Reina Sofía, Córdoba); Enrique Márquez
(Hospital Infanta Elena, Huelva); Manuel Rodríguez-Carvajal (Hospital
Juan Ramón Jiménez, Huelva); Ángel Estella (Hospital del SAS de Jerez,
Jerez de la Frontera); José Pomares, José Luis Ballesteros (Hospital
Universitario San Cecilio, Granada); Yolanda Fernández, Francisco Lobato,
José F. Prieto, José Albofedo-Sánchez (Hospital Costa del Sol, Marbella);
Pilar Martínez; María Victoria de la Torre; María Nieto (Hospital Vírgen de la
Victoria, Málaga); Miguel Angel Díaz Castellanos, (Hospital Santa Ana de
Motril, Granada); Guillermo Sevilla, (Clínica Sagrado Corazón, Sevilla);
José Garnacho-Montero, Rafael Hinojosa, Esteban Fernández, (Hospital
Virgen del Rocío, Sevilla); Ana Loza, Cristóbal León (Hospital Universitario
Nuestra Señora de Valme, Sevilla); Angel Arenzana (Hospital Virgen de
la Macarena, Sevilla), Dolores Ocaña (Hospital de la Inmaculada, Sevilla),
Inés Navarrete (Hospital Virgen de las Nieves, Granada), Medhi Zaheri
Beryanaki (Hospital de Antequera); Ignacio Sánchez (Hospital NISA Sevilla
ALJARAFE, Sevilla)
Aragón:
Manuel Luis Avellanas, Arantxa Lander, S Garrido Ramírez de Arellano, MI
Marquina Lacueva (Hospital San Jorge, Huesca); Pilar Luque; Elena Plumed
Serrano; Juan Francisco Martín Lázaro (Hospital Lozano Blesa, Zaragoza);
Ignacio González (Hospital Miquel Servet, Zaragoza); Jose Mª Montón
Martin-Loeches et al. Critical Care 2011, 15:R286
http://ccforum.com/content/15/6/R286
Page 8 of 11(Hospital Obispo Polanco, Teruel); Paloma Dorado Regil (Hospital Royo
Villanova, Zaragoza)
Asturias:
Lisardo Iglesias, Carmen Pascual González (Hospital Universitario Central
de Asturias - HUCA, Oviedo); Quiroga (Hospital De Cabueñes, Gijón);
Águeda García-Rodríguez (Hospital Valle del Nalón, Langreo)
Baleares:
Lorenzo Socias, Pedro Ibánez, Marcío Borges-Sa; A. Socias, Del Castillo A
(Hospital Son LLatzer, Palma de Mallorca); Ricard Jordà Marcos (Clínica
Rotger, Palma de Mallorca); José M Bonell (USP. Clínica Palmaplanas,
Palma de Mallorca); Ignacio Amestarán (Hospital Son Dureta, Palma de
Mallorca)
Canarias:
Sergio Ruiz- Santana, Juan José Díaz, (Hospital Dr Negrín, Las Palmas de
Gran Canaria); Sisón Juan (Hospital Doctor José Molina, Lanzarote);
David Hernández, Ana Trujillo, Luis Regalado (Hospital General la Palma,
La Palma); Leonardo Lorente (Hospital Universitario de Canarias,
Tenerife); Mar Martín (Hospital de la Candelaria, Tenerife); Sergio
Martínez, J. J. Cáceres (Hospital Insular de Gran Canaria)
Cantabria: Borja Suberviola, P. Ugarte (Hospital Universitario Marqués de
Valdecilla, Santander)
Castilla La Mancha:
Fernando García-López, (Hospital General, Albacete); Angel Álvaro Alonso,
Antonio Pasilla (Hospital General La Mancha Centro, Alcázar de San
Juan); Mª Luisa Gómez Grande (Hospital General de Ciudad Real, Ciudad
Real); Antonio Albaya (Hospital Universitario de Guadalajara,
Guadalajara); Alfonso Canabal, Luis Marina (Hospital Virgen de la Salud,
Toledo); Almudena Simón (Hospital Nuestra Señora del Prado, Toledo);
José María Añón (Hospital Virgen de la Luz, Cuenca)
Castilla y León:
Juan B López Messa (Complejo Asistencial de Palencia, Palencia); Mª
Jesús López Pueyo, Ortíz María del Valle (Hospital General Yagüe, Burgos);
Zulema Ferreras (Hospital Universitario de Salamanca, Salamanca);
Santiago Macias (Hospital General de Segovia, Segovia); José Ángel
Berezo, Jesús;Blanco Varela (Hospital Universitario Río Hortega,
Valladolid), Andaluz Ojeda A (Hospital Universitario, Valladolid); Antonio
Álvarez Terrero (Hospital Virgen de la Concha, Zamora); Fabiola Tena
Ezpeleta (Hospital Santa Bárbara, Soria); Zulema Paez, Álvaro García
(Hospital Virgen Vega, Salamanca)
Cataluña:
Rosa Mª Catalán ( Hospital General de Vic, Vic); Miquel Ferrer, Antoni
Torres, Catia Cilloniz (Hospital Clínic, Barcelona); Sandra Barbadillo
(Hospital General de Catalunya - CAPIO, Barcelona); Lluís Cabré, Ignacio
Baeza (Hospital de Barcelona, Barcelona); Assumpta Rovira (Hospital
General de l’Hospitalet, L’Hospitalet); Francisco Álvarez-Lerma, Antonia
Vázquez, Joan Nolla (Hospital Del Mar, Barcelona); Francisco Fernández,
Joaquim Ramón Cervelló; Raquel Iglesia (Centro Médico Delfos,
Barcelona); Rafael Mañéz, J. Ballús, Rosa Mª Granada (Hospital de Bellvitge,
Barcelona); Jordi Vallés, Marta Ortíz, C. Guía (Hospital de Sabadell,
Sabadell); Fernando Arméstar, Joaquim Páez (Hospital Dos De Mayo,
Barcelona); Jordi Almirall, Xavier Balanzo (Hospital de Mataró, Mataró);
Jordi Rello, Elena Arnau, Marcos Pérez, César Laborda, Jesica Souto, Mercedes
Palomar (Hospital Vall d’Hebron, Barcelona); Iñaki Catalán (Hospital Sant
Joan de Déu, Manresa); Josep Mª Sirvent, Cristina Ferri, Nerea López de
Arbina (Hospital Josep Trueta, Girona); Mariona Badía, Montserrat
Valverdú- Vidal, Fernando Barcenilla (Hospital Arnau de Vilanova, Lleida);
Mònica Magret (Hospital Sant Joan de Reus, Reus); MF Esteban, José Luna
(Hospital Verge de la Cinta, Tortosa); Juan Mª Nava, J González de Molina
(Hospital Universitario Mutua de Terrassa, Terrassa); Zoran Josic
(Hospital de Igualada, Igualada); Francisco Gurri, Paula Rodríguez
(Hospital Quirón, Barcelona); Alejandro Rodríguez, Thiago Lisboa, Ángel
Pobo, Sandra Trefler (Hospital Universitario Joan XXIII, Tarragona); Rosa
María Díaz (Hospital San Camil. Sant Pere de Ribes, Barcelona); Eduard
Mesalles (Hospital Germans Trias i Pujol, Badalona); Diego de Mendoza
(Hospital M. Broggi, Sant Joan Despí)
Extremadura:
Juliá-Narváez José (Hospital Infanta Cristina, Badajóz); Alberto Fernández-
Zapata, Teresa Recio, Abilio Arrascaeta, Mª José García-Ramos, Elena Gallego
(Hospital San Pedro de Alcántara, Cáceres); Fernándo Bueno (Hospital
Virgen del Puerto, Plasencia); Mercedes Díaz (Hospital de Mérida,
Mérida)
Galicia:
Mª Lourdes Cordero, José A. Pastor, Luis Álvarez - Rocha (CHUAC, A
Coruña); Dolores Vila, (Hospital Do Meixoeiro, Vigo); Ana Díaz Lamas
(Hospital Arquitecto Marcide, Ferrol); Javier Blanco Pérez, M Ortiz Piquer,
(Hospital Xeral - Calde, Lugo); Eleuterio Merayo, Victor Jose López-Ciudad,
Juan Cortes Cañones, Eva Vilaboy, José Villar Chao (Complejo Hospitalario
de Ourense, Ourense); Eva Maria Saborido, (Hospital Montecelo,
Pontevedra); Raul José González, (H. Miguel Domínguez, Pontevedra);
Santiago Freita, Enrique Alemparte; Ana Ortega (Complejo Hospitalario de
Pontevedra, Pontevedra); Ana María López; Julio Canabal, Enrique Ferres
(Clinica Universitaria Santiago de Compostela, Santiago)
La Rioja:
José Luis Monzón, Félix Goñi (Hospital San Pedro, Logroño).
Madrid:
Frutos Del Nogal Sáez, M Blasco Navalpotro (Hospital Severo Ochoa,
Madrid); Mª Carmen García-Torrejón, (Hospital Infanta Elena, Madrid);
César Pérez-Calvo, Diego López (Fundación Jiménez Díaz, Madrid); Luis
Arnaiz, S. Sánchez- Alonso, Carlos Velayos (Hospital Fuenlabrada, Madrid);
Francisco del Río, Miguel Ángel González (Hospital Clínico San Carlos,
Madrid); María Cruz Martín, José Mª Molina (Hospital Nuestra Señora de
América, Madrid); Juan Carlos Montejo, Mercedes Catalán (Hospital
Universitario 12 de Octubre, Madrid); Patricia Albert, Ana de Pablo
(Hospital del Sureste, Arganda del Rey); José Eugenio Guerrero, María
Zurita, Jaime Benitez Peyrat (Hospital Gregorio Marañón, Madrid); Enrique
Cerdá, Manuel Alvarez, Carlos Pey, (Hospital Infanta Cristina, Madrid);
Montse Rodríguez, Eduardo Palencia (Hospital Infanta Leonor, Madrid);
Rafael Caballero (Hospital de San Rafael, Madrid); Concepción Vaquero,
Francisco Mariscal, S. García (Hospital Infanta Sofía, Madrid); Nieves
Carrasco (Hospital Universitario La Princesa, Madrid); Isidro Prieto, A
Liétor, R. Ramos (Hospital Ramón y Cajal, Madrid); Beatríz Galván, Juan C.
Figueira, M. Cruz Soriano (Hospital La Paz, Madrid); P Galdós, Bárbara
Balandin Moreno (Hospital Puerta de Hierro, Madrid); Fernández del Cabo
(Hospital Monte Príncipe, Madrid); Cecilia Hermosa, Federico Gordo
(Hospital de Henares, Madrid); Alejandro Algora (Hospital Universitario
Fundación Alcorcón, Madrid); Amparo Paredes (Hospital Sur de
Alcorcón, Madrid); JA Cambronero (Hospital Universitario Príncipe de
Asturias, Madrid); Sonia Gómez-Rosado, (Hospital de Móstoles, Madrid);
Luis Miguel Prado López (Hospital Sanitas La Zarzuela, Madrid); Esteban
A, Lorente JA, Nin N (Hospital de Getafe, Madrid)
Murcia:
Sofía Martínez (Hospital Santa María del Rosell, Murcia); F. Felices Abad,
(Hospital Universitario Reina Sofía, Murcia); Mariano Martínez (Hospital
Universitario Virgen de la Arrixaca, Murcia); Sergio Manuel Butí, Bernardo
Gil Rueda, Francisco García (Hospital Morales Messeguer, Murcia)
Navarra:
Laura Macaya, Enrique Maraví-Poma, I Jimenez Urra, L Macaya Redin, A
Tellería (Hospital Virgen del Camino, Pamplona); Josu Insansti (Hospital
de Navarra, Pamplona)
País Vasco:
Nagore González, Pilar Marco, Loreto Vidaur (Hospital de Donostia, San
Sebastián); B. Santamaría, Tomás Rodríguez (Hospital de Basurto, Bilbao);
Juan Carlos Vergara, Jose Ramon Iruretagoyena Amiano (Hospital de
Cruces, Bilbao); Alberto Manzano, (Hospital Santiago Apóstol, Vitoria);
Carlos Castillo Arenal (Hospital Txagorritxu, Vitoria); Pedro María Olaechea,
Higinio Martín (Hospital Galdakao-Usansolo, Vizcaya)
Andorra:
Antoni Ribas (Hospital Nuestra Señora de Meritxell, Andorra)
Valencia:
José Blanquer (Hospital Clinic Universitari, Valencia); Roberto Reig Valero,
A. Belenger, Susana Altaba (Hospital General de Castellón, Castellón);
Bernabé Álvarez -Sánchez (Hospital General de Alicante, Alicante);
Santiago Alberto Picos (Hospital Torrevieja Salud, Alicante); Ángel
Sánchez-Miralles, (Hospital San Juan, Alicante); Juan Bonastre, M. Palamo,
Javier Cebrian, José Cuñat ( Hospital La Fe, Valencia); Belén Romero
(Hospital de Manises, Valencia); Rafael Zaragoza, Constantino Tormo
(Hospital Dr Peset, Valencia); Virgilio Paricio, (Hospital de Requena,
Valencia); Asunción Marques, S. Sánchez-Morcillo, S. Tormo (Hospital de la
Ribera, Valencia); J. Latour (H.G Universitario de Elche, Valencia); M
Ángel García (Hospital de Sagunto, Castellón)
Martin-Loeches et al. Critical Care 2011, 15:R286
http://ccforum.com/content/15/6/R286
Page 9 of 11Author details
1Critical Care Center, Parc Taulí Hospital-Sabadell, CIBERes, Sabadell, Spain.
2Critical Care Department, Hospital Joan XXIII/CIBERES/IISPV/URV- Tarragona,
Spain.
3Critical Care Department, Hospital Donostia/CIBERES - San Sebastian,
Spain.
4Pneumology Department, Hospital Clínic of Barcelona, IDIBAPS,
Centro de Investigación Biomédica en Red-Enfermedades Respiratorias
(CIBERES, CB06/06/0028), University of Barcelona, Barcelona, Spain.
5Critical
Care Department. Hospital Vall d’Hebron/CIBERES/IRVH - Barcelona, Spain.
6Critical Care Department, Hospital de Bellvitge/CIBERES - Barcelona, Spain.
7Critical Care Department, Hospital La Fe -Valencia, Spain.
8Critical Care
Department, Hospital La Candelaria - Tenerife, Spain.
9Critical Care
Department, Hospital de Navarra - Pamplona, Spain.
10Critical Care
Department, Hospital V. de la Macarena/CIBERES - Sevilla, Spain.
11Critical
Care Department, Hospital G.Marañón/CIBERES - Madrid, Spain.
12Critical Care
Department, Hospital V. de las Nieves - Granada, Spain.
13Infection and
Immunity Unit, Hospital Clínico Universitario-IECSCYL, Valladolid, Spain.
14Epidemiology and Assessment Unit, Fundació Parc Tauli, Universitat
Autònoma de Barcelona, Sabadell, Spain.
Authors’ contributions
IML made a substantial contribution. AR and IML assisted in the design of
the study, coordinated patient recruitment, analyzed and interpreted the
data and assisted in writing the paper. LV, CL, RG, JI, JEG, JB, AA and IN
made important contributions to the acquisition and analysis of data. AT
and JFBM were involved in revising the manuscript critically for important
intellectual content. IML, AR, DS and ED made substantial contributions to
the conception, design, analysis and interpretation of data and revised the
final manuscript version. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests
Received: 5 July 2011 Revised: 25 November 2011
Accepted: 28 November 2011 Published: 28 November 2011
References
1. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M,
Quiñones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J,
Ormsby CE, Corrales A, Higuera A, Mondragon E, Cordova-Villalobos JA,
INER Working Group on Influenza: Pneumonia and respiratory failure from
swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009,
361:680-689.
2. The ANZIC Influenza Investigators: Critical care services and 2009 H1N1
influenza in Australia and New Zealand. N Engl J Med 2009,
361:1925-1934.
3. Rodríguez A, Díaz E, Martín-Loeches I, Sandiumenge A, Canadell L, Díaz JJ,
Figueira JC, Marques A, Alvarez-Lerma F, Vallés J, Baladín B, García-López F,
Suberviola B, Zaragoza R, Trefler S, Bonastre J, Blanquer J, Rello J, H1N1
SEMICYUC Working Group: Impact of early oseltamivir treatment on
outcome in critically ill patients with 2009 pandemic influenza A. J
Antimicrob Chemother 2011, 66:1140-1149.
4. Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M:
Benefit of early treatment with oseltamivir in hospitalized patients with
documented 2009 influenza A (H1N1): retrospective cohort study. J
Antimicrob Chemother 2011, 66:1150-1155.
5. Martin-Loeches I, Lisboa T, Rhodes A, Moreno RP, Silva E, Sprung C,
Chiche JD, Barahona D, Villabon M, Balasini C, Pearse RM, Matos R, Rello J,
ESICM H1N1 Registry Contributors: Use of early corticosteroid therapy on
ICU admission in patients affected by severe pandemic (H1N1)v
influenza A infection. Intensive Care Med 2011, 37:272-283.
6. Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, Lee YJ, Lee HB, Lim CM, Koh Y,
Korean Society of Critical Care Medicine H1N1 Collaborative: corticosteroid
treatment in critically ill patients with pandemic Influenza A/H1N1 2009
Infection: analytic strategy using propensity scores. Am J Respir Crit Care
Med 2011, 183:1207-1214.
7. Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R,
Villavicencio C, Albaya A, Cerdá E, Catalán RM, Luque P, Paredes A,
Navarrete I, Rello J, Rodríguez A, H1N1 SEMICYUC Working Group:
Community-acquired respiratory co-infection (CARC)in critically ill
patients infected with pandemic 2009 influenza A (H1N1) virus infection.
Chest 2011, 139:555-562.
8. Díaz E, Rodríguez A, Martin-Loeches I, Lorente L, del Mar Martín M, Pozo JC,
Montejo JC, Estella A, Arenzana A, Rello J, H1N1 SEMICYUC Working Group:
Impact of obesity in patients infected with new influenza A (H1N1)v.
Chest 2011, 139:382-386.
9. Martin-Loeches I, Papiol E, Rodríguez A, Diaz E, Zaragoza R, Granada RM,
Socias L, Bonastre J, Valverdú M, Pozo JC, Luque P, Juliá-Narvaéz JA,
Cordero L, Albaya A, Serón D, Rello J, the H1N1 SEMICYUC Working Group:
Acute kidney injury in critical ill patients affected by influenza A (H1N1)
virus infection. Crit Care 2011, 15:R66.
10. Influenza A(H1N1) 2009 virus: current situation and post-pandemic
recommendations. Wkly Epidemiol Rec 2011, 86:61-65.
11. Rello J, Rodríguez A, Ibañez P, Socias L, Cebrian J, Marques A, Guerrero J,
Ruiz-Santana S, Marquez E, Del Nogal-Saez F, Alvarez-Lerma F, Martínez S,
Ferrer M, Avellanas M, Granada R, Maraví-Poma E, Albert P, Sierra R,
Vidaur L, Ortiz P, Prieto del Portillo I, Galván B, León-Gil C, H1N1 SEMICYUC
Working Group: Intensive care adult patients with severe respiratory
failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009, 13:R148.
12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J,
Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS 2001: SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit
Care Med 2003, 31:1250-1256.
13. American Thoracic Society; Infectious Diseases Society of America:
Guidelines for the management of adults with hospital-acquired,
ventilator-associated, and healthcare-associated pneumonia. Am J Respir
Crit Care Med 2005, 171:388-416.
14. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A,
Acute Kidney Injury Network: Acute Kidney Injury Network: report of an
initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:
R31.
15. Helferty M, Vachon J, Tarasuk J, Rodin R, Spika J, Pelletier L: Incidence of
hospital admissions and severe outcomes during the first and second
waves of pandemic (H1N1) 2009. CMAJ 2010, 182:1981-1987.
16. Sistema de Vigilancia de la Gripe en España. [http://vgripe.isciii.es/gripe].
17. Smith JR, Ariano RE, Toovey S: The use of antiviral agents for the
management of severe influenza. Crit Care Med 2010, 38(4 Suppl):e43-51.
18. Hurt AC, Deng YM, Ernest J, Caldwell N, Leang L, Iannello P, Komadina N,
Shaw R, Smith D, Dwyer DE, Tramontana AR, Lin RT, Freeman K, Kelso A,
Barr IG: Oseltamivir-resistant influenza viruses circulating during the first
year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region,
March 2009 to March 2010. Euro Surveill 2011, 16:19770.
19. Li IW, Hung IF, To KK, Chan KH, Wong SS, Chan JF, Cheng VC, Tsang OT,
Lai ST, Lau YL, Yuen KY: The natural viral load profile of patients with
pandemic 2009 influenza A(H1N1) and the effect of oseltamivir
treatment. Chest 2010, 137:759-768.
20. Ling LM, Chow AL, Lye DC, Tan AS, Krishnan P, Cui L, Win NN, Chan M,
Lim PL, Lee CC, Leo YS: Effects of early oseltamivir therapy on viral
shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect
Dis 2010, 50:963-969.
21. Jegerlehner A, Schmitz N, Storni T, Bachmann MF: Influenza A vaccine
based on the extracellular domain of M2: weak protection mediated via
antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
22. Cheng VC, Lau YK, Lee KL, Yiu KH, Chan KH, Ho PL, Yuen KY: Fatal co-
infection with swine origin influenza virus A/H1N1 and community-
acquired methicillin-resistant Staphylococcus aureus. J Infect 2009,
59:366-370.
23. Riera M, Payeras A, Marcos MA, Viasus D, Farinas MC, Segura F, Torre-
Cisneros J, Martín-Quirós A, Rodríguez-Baño J, Vila J, Cordero E, Carratalà J:
Clinical presentation and prognosis of the 2009 H1N1 influenza A
infection in HIV-1-infected patients: a Spanish multicenter study. AIDS
2010, 24:2461-2467.
24. van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ: Bench-
to-bedside review: bacterial pneumonia with influenza - pathogenesis
and clinical implications. Crit Care 2010, 14:219.
25. Manuell ME, Co MD, Ellison RT: Pandemic influenza: implications for
preparation and delivery of critical care services. J Intensive Care Med
2011, 26:347-367.
26. Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial
pneumonia as a cause of death in pandemic influenza: implications for
pandemic influenza preparedness. J Infect Dis 2008, 198:962-970.
Martin-Loeches et al. Critical Care 2011, 15:R286
http://ccforum.com/content/15/6/R286
Page 10 of 1127. Brundage JF: Interactions between influenza and bacterial respiratory
pathogens: implications for pandemic preparedness. Lancet Infect Dis
2006, 6:303-312.
28. Bellomo R, Pettilä V, Webb SA, Bailey M, Howe B, Seppelt IM: Acute kidney
injury and 2009 H1N1 influenza-related critical illness. Contrib Nephrol
2010, 165:310-314.
29. Trimarchi H, Greloni G, Campolo-Girard V, Giannasi S, Pomeranz V, San-
Roman E, Lombi F, Barcan L, Forrester M, Algranati S, Iriarte R, Rosa-Diez G:
H1N1 infection and the kidney in critically ill patients. J Nephrol 2010,
23:725-731.
30. Japiassú AM, Amâncio RT, Mesquita EC, Medeiros DM, Bernal HB, Nunes EP,
Luz PM, Grinsztejn B, Bozza FA: Sepsis is a major determinant of outcome
in critically ill HIV/AIDS patients. Crit Care 2010, 14:R152.
31. Vincent B, Timsit JF, Auburtin M, Schortgen F, Bouadma L, Wolff M,
Regnier B: Characteristics and outcomes of HIV-infected patients in the
ICU: impact of the highly active antiretroviral treatment era. Intensive
Care Med 2004, 30:859-866.
doi:10.1186/cc10573
Cite this article as: Martin-Loeches et al.: Pandemic and post-pandemic
Influenza A (H1N1) infection in critically ill patients. Critical Care 2011 15:
R286.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Martin-Loeches et al. Critical Care 2011, 15:R286
http://ccforum.com/content/15/6/R286
Page 11 of 11